Alectinib bulk supplier for pharma manufacturers

Alectinib 150 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 150 mg

Reference Brands: Alecensa (USA/EU)

Alectinib is an oral anticancer medication used for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It works as a tyrosine kinase inhibitor (TKI) that specifically targets and blocks the activity of the anaplastic lymphoma kinase (ALK) protein, which promotes the growth of cancer cells. By inhibiting ALK, alectinib helps slow or stop the spread of cancer.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Alectinib — third party manufacturing & bulk supply

Alectinib 150 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Alectinib is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Alectinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Alectinib →

Back to Listing

Frequently Asked Questions

Alectinib is listed as Capsules in 150 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Alectinib is referenced against Alecensa (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.